{"id": "article-31430_0", "title": "X-Linked Agammaglobulinemia -- Continuing Education Activity", "content": "X-linked agammaglobulinemia or XLA is a primary immunodeficiency disorder that prevents affected individuals from making antibodies and requires them to rely on lifelong immunoglobulin replacement therapy for survival. Without immunoglobulins (or antibodies), XLA patients are rendered vulnerable to invasive infections. Hospitalization for bacterial pneumonia, requiring intravenous antibiotics for resolution, is usually what prompts the diagnostic work-up for primary immunodeficiency. This activity reviews the pathophysiology of XLA and highlights the role of the interprofessional team in its management.", "contents": "X-Linked Agammaglobulinemia -- Continuing Education Activity. X-linked agammaglobulinemia or XLA is a primary immunodeficiency disorder that prevents affected individuals from making antibodies and requires them to rely on lifelong immunoglobulin replacement therapy for survival. Without immunoglobulins (or antibodies), XLA patients are rendered vulnerable to invasive infections. Hospitalization for bacterial pneumonia, requiring intravenous antibiotics for resolution, is usually what prompts the diagnostic work-up for primary immunodeficiency. This activity reviews the pathophysiology of XLA and highlights the role of the interprofessional team in its management."}
{"id": "article-31430_1", "title": "X-Linked Agammaglobulinemia -- Continuing Education Activity", "content": "Objectives: Identify the etiology of X-linked agammaglobulinemia. Review the evaluation process for X-linked agammaglobulinemia. Outline the treatment and management options available for X-linked agammaglobulinemia. Summarize interprofessional team strategies for improving care coordination and communication to advance X-linked agammaglobulinemia and improve outcomes. Access free multiple choice questions on this topic.", "contents": "X-Linked Agammaglobulinemia -- Continuing Education Activity. Objectives: Identify the etiology of X-linked agammaglobulinemia. Review the evaluation process for X-linked agammaglobulinemia. Outline the treatment and management options available for X-linked agammaglobulinemia. Summarize interprofessional team strategies for improving care coordination and communication to advance X-linked agammaglobulinemia and improve outcomes. Access free multiple choice questions on this topic."}
{"id": "article-31430_2", "title": "X-Linked Agammaglobulinemia -- Introduction", "content": "X-linked agammaglobulinemia or XLA is one of the most common pediatric primary immunodeficiencies that prevent affected individuals from making antibodies and requires lifelong immunoglobulin replacement therapy for survival. [1]", "contents": "X-Linked Agammaglobulinemia -- Introduction. X-linked agammaglobulinemia or XLA is one of the most common pediatric primary immunodeficiencies that prevent affected individuals from making antibodies and requires lifelong immunoglobulin replacement therapy for survival. [1]"}
{"id": "article-31430_3", "title": "X-Linked Agammaglobulinemia -- Introduction", "content": "The molecular basis for XLA\u00a0is a\u00a0disruption in B cell development due to mutation in Bruton's tyrosine kinase (Btk). Affected individuals\u00a0inherit\u00a0a defect that prevents\u00a0precursor B cells in the bone marrow from forming mature, circulating B-lymphocytes that would otherwise be capable of proliferating and differentiating into antibody-producing plasma cells in secondary lymphoid\u00a0organs like the\u00a0tonsils and\u00a0lymph nodes. This dysfunction results in\u00a0dangerously\u00a0low, clinically undetectable\u00a0levels\u00a0of all immunoglobulin isotypes in the serum. [2] [3] [4]", "contents": "X-Linked Agammaglobulinemia -- Introduction. The molecular basis for XLA\u00a0is a\u00a0disruption in B cell development due to mutation in Bruton's tyrosine kinase (Btk). Affected individuals\u00a0inherit\u00a0a defect that prevents\u00a0precursor B cells in the bone marrow from forming mature, circulating B-lymphocytes that would otherwise be capable of proliferating and differentiating into antibody-producing plasma cells in secondary lymphoid\u00a0organs like the\u00a0tonsils and\u00a0lymph nodes. This dysfunction results in\u00a0dangerously\u00a0low, clinically undetectable\u00a0levels\u00a0of all immunoglobulin isotypes in the serum. [2] [3] [4]"}
{"id": "article-31430_4", "title": "X-Linked Agammaglobulinemia -- Introduction", "content": "Without immunoglobulins (or antibodies),\u00a0XLA patients\u00a0are rendered vulnerable to invasive infections from encapsulated bacteria (such as Streptococcus pneumoniae , Staphylococcus aureus ,\u00a0and Haemophilus influenzae ), have an increased incidence of enterovirus infections\u00a0(e.g., poliovirus, coxsackievirus, echovirus), and chronic diarrhea (from Giardia lamblia ). [5] [6] [7]", "contents": "X-Linked Agammaglobulinemia -- Introduction. Without immunoglobulins (or antibodies),\u00a0XLA patients\u00a0are rendered vulnerable to invasive infections from encapsulated bacteria (such as Streptococcus pneumoniae , Staphylococcus aureus ,\u00a0and Haemophilus influenzae ), have an increased incidence of enterovirus infections\u00a0(e.g., poliovirus, coxsackievirus, echovirus), and chronic diarrhea (from Giardia lamblia ). [5] [6] [7]"}
{"id": "article-31430_5", "title": "X-Linked Agammaglobulinemia -- Introduction", "content": "XLA patients commonly present with a history of recurrent upper respiratory tract infections, including sinusitis and otitis media, beginning after 6 to 9 months when most of the maternal antibodies have been exhausted.\u00a0 However, hospitalization for bacterial pneumonia, requiring intravenous antibiotics for resolution, is usually what prompts the diagnostic work-up for immune deficiency disease. The average age of diagnosis is 2.5 years, and almost\u00a0all cases of XLA get diagnosed before\u00a05 years of age. Notably, late-onset forms of XLA also exist. [8]", "contents": "X-Linked Agammaglobulinemia -- Introduction. XLA patients commonly present with a history of recurrent upper respiratory tract infections, including sinusitis and otitis media, beginning after 6 to 9 months when most of the maternal antibodies have been exhausted.\u00a0 However, hospitalization for bacterial pneumonia, requiring intravenous antibiotics for resolution, is usually what prompts the diagnostic work-up for immune deficiency disease. The average age of diagnosis is 2.5 years, and almost\u00a0all cases of XLA get diagnosed before\u00a05 years of age. Notably, late-onset forms of XLA also exist. [8]"}
{"id": "article-31430_6", "title": "X-Linked Agammaglobulinemia -- Introduction", "content": "There is currently\u00a0no cure for XLA; however, early management with immunoglobulin replacement therapy and\u00a0antibiotics to prevent and treat infections. Although this lifelong avenue is costly, it has been the mainstay of treatment for the past fifty years.\u00a0Any significant delay in diagnosis poses\u00a0the danger of developing chronic, treatment-resistant infections, and end-organ damage that cannot be corrected. [9] [3]", "contents": "X-Linked Agammaglobulinemia -- Introduction. There is currently\u00a0no cure for XLA; however, early management with immunoglobulin replacement therapy and\u00a0antibiotics to prevent and treat infections. Although this lifelong avenue is costly, it has been the mainstay of treatment for the past fifty years.\u00a0Any significant delay in diagnosis poses\u00a0the danger of developing chronic, treatment-resistant infections, and end-organ damage that cannot be corrected. [9] [3]"}
{"id": "article-31430_7", "title": "X-Linked Agammaglobulinemia -- Etiology", "content": "XLA results from mutation of the\u00a0Bruton's tyrosine kinase gene (Btk)\u00a0located\u00a0on the long arm (q) of the X chromosome (Xq21.3-Xq22), affecting males almost exclusively. Hundreds of\u00a0different mutations\u00a0have been reported to cause XLA,\u00a0including missense, frameshift, deletion, insertion, premature stop codon, and point\u00a0mutations. The molecular location of these mutations encompasses\u00a0base pairs 101349447 to 101390796 on the X chromosome. However, no single mutation correlates with more than 3% of the known cases. [10] [11]", "contents": "X-Linked Agammaglobulinemia -- Etiology. XLA results from mutation of the\u00a0Bruton's tyrosine kinase gene (Btk)\u00a0located\u00a0on the long arm (q) of the X chromosome (Xq21.3-Xq22), affecting males almost exclusively. Hundreds of\u00a0different mutations\u00a0have been reported to cause XLA,\u00a0including missense, frameshift, deletion, insertion, premature stop codon, and point\u00a0mutations. The molecular location of these mutations encompasses\u00a0base pairs 101349447 to 101390796 on the X chromosome. However, no single mutation correlates with more than 3% of the known cases. [10] [11]"}
{"id": "article-31430_8", "title": "X-Linked Agammaglobulinemia -- Etiology", "content": "The gene for Btk codes for a cytoplasmic tyrosine kinase protein, BTK,\u00a0which acts as a\u00a0signal transducer driving the\u00a0final stages of B cell maturation. The inheritance of disease-causing mutation of the Btk gene interferes with BTK protein expression,\u00a0resulting in the arrest of differentiation at the\u00a0pre-B-cell stage in the bone marrow, causing a profound lack of mature B lymphocytes in the peripheral circulation and\u00a0a corresponding absence or severe reduction\u00a0in all immunoglobulin isotypes\u00a0from\u00a0the serum. [12]", "contents": "X-Linked Agammaglobulinemia -- Etiology. The gene for Btk codes for a cytoplasmic tyrosine kinase protein, BTK,\u00a0which acts as a\u00a0signal transducer driving the\u00a0final stages of B cell maturation. The inheritance of disease-causing mutation of the Btk gene interferes with BTK protein expression,\u00a0resulting in the arrest of differentiation at the\u00a0pre-B-cell stage in the bone marrow, causing a profound lack of mature B lymphocytes in the peripheral circulation and\u00a0a corresponding absence or severe reduction\u00a0in all immunoglobulin isotypes\u00a0from\u00a0the serum. [12]"}
{"id": "article-31430_9", "title": "X-Linked Agammaglobulinemia -- Etiology", "content": "While\u00a0the majority of agammaglobulinemia cases result from X-linked inheritance of Btk gene mutations, approximately 10% of the cases are the result of autosomal gene mutations. The resulting condition is known as autosomal recessive agammaglobulinemia(ARA) and describes the clinical phenotype\u00a0seen in females\u00a0with congenital agammaglobulinemia,\u00a0which is\u00a0comparable to XLA in males. The molecular defects responsible for\u00a0ARA include mutations to the following genes:\u00a0mu heavy chain (UGHN); gamma 5 (IGLL1); Igalpha (CD79A); Igbeta (CD79B); and BLNK. The wild-type\u00a0proteins encoded by these genes\u00a0have been shown to\u00a0operate in collaboration\u00a0with BTK,\u00a0to promote the transition from pro-B-cells to pre-B-cells in the bone marrow, during B cell maturation. [13] [14] [10]", "contents": "X-Linked Agammaglobulinemia -- Etiology. While\u00a0the majority of agammaglobulinemia cases result from X-linked inheritance of Btk gene mutations, approximately 10% of the cases are the result of autosomal gene mutations. The resulting condition is known as autosomal recessive agammaglobulinemia(ARA) and describes the clinical phenotype\u00a0seen in females\u00a0with congenital agammaglobulinemia,\u00a0which is\u00a0comparable to XLA in males. The molecular defects responsible for\u00a0ARA include mutations to the following genes:\u00a0mu heavy chain (UGHN); gamma 5 (IGLL1); Igalpha (CD79A); Igbeta (CD79B); and BLNK. The wild-type\u00a0proteins encoded by these genes\u00a0have been shown to\u00a0operate in collaboration\u00a0with BTK,\u00a0to promote the transition from pro-B-cells to pre-B-cells in the bone marrow, during B cell maturation. [13] [14] [10]"}
{"id": "article-31430_10", "title": "X-Linked Agammaglobulinemia -- Epidemiology", "content": "XLA exclusively affects males. The reported incidence and prevalence of XLA vary considerably. Some\u00a0sources report\u00a0that XLA\u00a0occurs at a rate of 1 in 190000 live births with a frequency of 1 per 100000 newborn males, and an estimated\u00a0prevalence\u00a0of 1 to 9 per 1000000. [10] There is\u00a0no\u00a0known ethnic predisposition,\u00a0but the reported incidence is highest in individuals of the White race. [15] [16]", "contents": "X-Linked Agammaglobulinemia -- Epidemiology. XLA exclusively affects males. The reported incidence and prevalence of XLA vary considerably. Some\u00a0sources report\u00a0that XLA\u00a0occurs at a rate of 1 in 190000 live births with a frequency of 1 per 100000 newborn males, and an estimated\u00a0prevalence\u00a0of 1 to 9 per 1000000. [10] There is\u00a0no\u00a0known ethnic predisposition,\u00a0but the reported incidence is highest in individuals of the White race. [15] [16]"}
{"id": "article-31430_11", "title": "X-Linked Agammaglobulinemia -- Epidemiology", "content": "Common aliases for X-linked agammaglobulinemia include Bruton agammaglobulinemia, Btk agammaglobulinemia, Bruton tyrosine kinase agammaglobulinemia, agammaglobulinemia of Bruton, and congenital agammaglobulinemia.", "contents": "X-Linked Agammaglobulinemia -- Epidemiology. Common aliases for X-linked agammaglobulinemia include Bruton agammaglobulinemia, Btk agammaglobulinemia, Bruton tyrosine kinase agammaglobulinemia, agammaglobulinemia of Bruton, and congenital agammaglobulinemia."}
{"id": "article-31430_12", "title": "X-Linked Agammaglobulinemia -- Pathophysiology", "content": "When the disease-causing mutation affects a gene on the X chromosome, one copy of the mutant gene is sufficient to cause the condition. In theory, this means that XLA will affect\u00a050% of males born to mothers who are carriers. When the disease-causing mutations occur on genes\u00a0within autosomes, either gender may be affected, e.g., females with autosomal recessive agammaglobulinemia. Individuals with XLA have\u00a0one of several\u00a0inherited defects\u00a0in the Btk gene that interferes with the production of mature\u00a0B-lymphocytes\u00a0in circulation. T lymphocytes\u00a0are unaffected. [3]", "contents": "X-Linked Agammaglobulinemia -- Pathophysiology. When the disease-causing mutation affects a gene on the X chromosome, one copy of the mutant gene is sufficient to cause the condition. In theory, this means that XLA will affect\u00a050% of males born to mothers who are carriers. When the disease-causing mutations occur on genes\u00a0within autosomes, either gender may be affected, e.g., females with autosomal recessive agammaglobulinemia. Individuals with XLA have\u00a0one of several\u00a0inherited defects\u00a0in the Btk gene that interferes with the production of mature\u00a0B-lymphocytes\u00a0in circulation. T lymphocytes\u00a0are unaffected. [3]"}
{"id": "article-31430_13", "title": "X-Linked Agammaglobulinemia -- Pathophysiology", "content": "B cell development is a process that occurs in the bone marrow, where pro-B cells develop into pre-B cells before fully mature B cells enter the peripheral circulation. Normally, pre-B cells express the pre-BCR complex, which undergoes activation by BTK to initiate downstream signaling events involved in the maturation process. This process becomes blocked at the pre-B cell stage in individuals with inherited mutations that prevent BTK expression (figure 1). Western blotting or flow cytometry analysis of BTK protein expression in the monocytes or platelets of individuals with XLA demonstrates that it cannot be detected. [8] [6]", "contents": "X-Linked Agammaglobulinemia -- Pathophysiology. B cell development is a process that occurs in the bone marrow, where pro-B cells develop into pre-B cells before fully mature B cells enter the peripheral circulation. Normally, pre-B cells express the pre-BCR complex, which undergoes activation by BTK to initiate downstream signaling events involved in the maturation process. This process becomes blocked at the pre-B cell stage in individuals with inherited mutations that prevent BTK expression (figure 1). Western blotting or flow cytometry analysis of BTK protein expression in the monocytes or platelets of individuals with XLA demonstrates that it cannot be detected. [8] [6]"}
{"id": "article-31430_14", "title": "X-Linked Agammaglobulinemia -- Pathophysiology -- Figure 1. Precursor B Cell\u00a0\u00a0->\u00a0 Pro-B Cell\u00a0-l X l-\u00a0 Pre-B Cell\u00a0-> Immature B Cell", "content": "B cell differentiation becomes arrested at the\u00a0Pre-B cell stage with an\u00a0associated failure of immunoglobulin heavy chain rearrangement; this abrogates the production of immunoglobulins and\u00a0prevents secondary lymphoid organs from developing fully.", "contents": "X-Linked Agammaglobulinemia -- Pathophysiology -- Figure 1. Precursor B Cell\u00a0\u00a0->\u00a0 Pro-B Cell\u00a0-l X l-\u00a0 Pre-B Cell\u00a0-> Immature B Cell. B cell differentiation becomes arrested at the\u00a0Pre-B cell stage with an\u00a0associated failure of immunoglobulin heavy chain rearrangement; this abrogates the production of immunoglobulins and\u00a0prevents secondary lymphoid organs from developing fully."}
{"id": "article-31430_15", "title": "X-Linked Agammaglobulinemia -- Histopathology", "content": "Underdevelopment of lymphoid tissues, including the spleen, lymph nodes, tonsils, and Peyer's patches are visible on histology of tissue samples from patients with XLA. These findings, however, are not diagnostic of XLA.", "contents": "X-Linked Agammaglobulinemia -- Histopathology. Underdevelopment of lymphoid tissues, including the spleen, lymph nodes, tonsils, and Peyer's patches are visible on histology of tissue samples from patients with XLA. These findings, however, are not diagnostic of XLA."}
{"id": "article-31430_16", "title": "X-Linked Agammaglobulinemia -- History and Physical", "content": "A thorough\u00a0medical\u00a0history and physical exam is a requirement for all individuals suspected of having XLA.", "contents": "X-Linked Agammaglobulinemia -- History and Physical. A thorough\u00a0medical\u00a0history and physical exam is a requirement for all individuals suspected of having XLA."}
{"id": "article-31430_17", "title": "X-Linked Agammaglobulinemia -- History and Physical", "content": "In the case of infants or very young children, history is elicited through a careful interview of the parents or caretakers. Obtaining information about the general health status, past infections, hospitalizations, surgeries, vaccinations, vaccination reactions, allergies, and current and past medications is crucial. Knowledge of the patient\u2019s diet, home environment, social history, and travel activities may also be contributory.", "contents": "X-Linked Agammaglobulinemia -- History and Physical. In the case of infants or very young children, history is elicited through a careful interview of the parents or caretakers. Obtaining information about the general health status, past infections, hospitalizations, surgeries, vaccinations, vaccination reactions, allergies, and current and past medications is crucial. Knowledge of the patient\u2019s diet, home environment, social history, and travel activities may also be contributory."}
{"id": "article-31430_18", "title": "X-Linked Agammaglobulinemia -- History and Physical", "content": "A history of frequent, chronic, or recurrent infections, such as conjunctivitis, upper respiratory tract infections (e.g., pharyngitis; sinusitis; bronchitis; pneumonia), deep-seated skin infections (e.g., empyema), purulent otitis media, and diarrhea should raise suspicion. Patient records containing documented information of cultures found positive for encapsulated bacteria may help guide the diagnosis. Bacterial pneumonia, for example, is rare in infants and immunocompetent young children. Other important clues that can be used to direct the work-up include a history\u00a0indicating the need for IV antibiotics\u00a0to resolve infections, multiple hospitalizations before the age of 3 years, or\u00a0developmental\u00a0delay. [17] [18] A careful review of systems should be completed, with\u00a0special attention paid to the upper and lower respiratory, lymphatic, gastrointestinal, and integumentary systems.", "contents": "X-Linked Agammaglobulinemia -- History and Physical. A history of frequent, chronic, or recurrent infections, such as conjunctivitis, upper respiratory tract infections (e.g., pharyngitis; sinusitis; bronchitis; pneumonia), deep-seated skin infections (e.g., empyema), purulent otitis media, and diarrhea should raise suspicion. Patient records containing documented information of cultures found positive for encapsulated bacteria may help guide the diagnosis. Bacterial pneumonia, for example, is rare in infants and immunocompetent young children. Other important clues that can be used to direct the work-up include a history\u00a0indicating the need for IV antibiotics\u00a0to resolve infections, multiple hospitalizations before the age of 3 years, or\u00a0developmental\u00a0delay. [17] [18] A careful review of systems should be completed, with\u00a0special attention paid to the upper and lower respiratory, lymphatic, gastrointestinal, and integumentary systems."}
{"id": "article-31430_19", "title": "X-Linked Agammaglobulinemia -- History and Physical", "content": "XLA infants are born healthy, with no outward signs of impending illness, and do not develop recurrent infections until 6-8 months of age when maternal antibodies are no longer active.\u00a0 Although a history of recurrent infections beginning after 6 months of age is very characteristic of this disease, a physical exam is also important.\u00a0 Lymphoid tissues are\u00a0typically hypoplastic in XLA patients.\u00a0The tonsils may be difficult to visualize, and the cervical/inguinal lymph nodes may not be palpable. The otoscopic exam may be used to detect signs of chronic damage, i.e.,\u00a0purulent otitis media, perforation of the tympanic membrane,\u00a0or nasal discharge. Chest auscultation is performed to check for prolongation of\u00a0expiration\u00a0or inspiration, cough, any increase in\u00a0respiratory effort, or stridor. Audible\u00a0rhonchi, crackles, wheezing, and/or inspiratory squeaks suggest\u00a0lung\u00a0pathology and warrant further testing (e.g., lung function tests, CT scan, or biopsy) to rule out\u00a0bronchiectasis. Similarly, the presence of abdominal distention justifies the need to perform an abdominal ultrasound to exclude hepatosplenomegaly. [1]", "contents": "X-Linked Agammaglobulinemia -- History and Physical. XLA infants are born healthy, with no outward signs of impending illness, and do not develop recurrent infections until 6-8 months of age when maternal antibodies are no longer active.\u00a0 Although a history of recurrent infections beginning after 6 months of age is very characteristic of this disease, a physical exam is also important.\u00a0 Lymphoid tissues are\u00a0typically hypoplastic in XLA patients.\u00a0The tonsils may be difficult to visualize, and the cervical/inguinal lymph nodes may not be palpable. The otoscopic exam may be used to detect signs of chronic damage, i.e.,\u00a0purulent otitis media, perforation of the tympanic membrane,\u00a0or nasal discharge. Chest auscultation is performed to check for prolongation of\u00a0expiration\u00a0or inspiration, cough, any increase in\u00a0respiratory effort, or stridor. Audible\u00a0rhonchi, crackles, wheezing, and/or inspiratory squeaks suggest\u00a0lung\u00a0pathology and warrant further testing (e.g., lung function tests, CT scan, or biopsy) to rule out\u00a0bronchiectasis. Similarly, the presence of abdominal distention justifies the need to perform an abdominal ultrasound to exclude hepatosplenomegaly. [1]"}
{"id": "article-31430_20", "title": "X-Linked Agammaglobulinemia -- History and Physical", "content": "Finally, it is important not to overlook the family medical history, including information about past infections, hospitalizations, surgeries, previous diagnoses or symptoms of immunodeficiency, the ages and health status of living relatives, or causes of death.", "contents": "X-Linked Agammaglobulinemia -- History and Physical. Finally, it is important not to overlook the family medical history, including information about past infections, hospitalizations, surgeries, previous diagnoses or symptoms of immunodeficiency, the ages and health status of living relatives, or causes of death."}
{"id": "article-31430_21", "title": "X-Linked Agammaglobulinemia -- Evaluation", "content": "The definitive laboratory evaluation of XLA involves quantitating serum immunoglobulin levels, enumerating lymphocyte subsets, performing provocative antibody response tests, and conducting molecular and genetic analyses. [19] [20]", "contents": "X-Linked Agammaglobulinemia -- Evaluation. The definitive laboratory evaluation of XLA involves quantitating serum immunoglobulin levels, enumerating lymphocyte subsets, performing provocative antibody response tests, and conducting molecular and genetic analyses. [19] [20]"}
{"id": "article-31430_22", "title": "X-Linked Agammaglobulinemia -- Evaluation", "content": "A\u00a0typical\u00a0diagnostic test sequence would evaluate serum levels of IgG, IgM, and IgA, the number of CD19-positive or CD20-positive B cells in circulation, humoral vaccine responses, BTK protein expression in peripheral monocytes, and Btk gene sequencing. Test results consistent with a diagnosis of XLA in a male patient with a history of recurrent bacterial infections would include finding: Serum levels of IgG, IgM, and IgA that are more than two standard deviations below age-matched controls Absence of mature B lymphocytes in the peripheral circulation (i.e., fewer than 1-2%) Little or no increase in antibody titers 3-4 weeks after\u00a0protein- or polysaccharide antigen vaccines\u00a0(e.g.,\u00a0immunizing against pneumococcal pneumonia or diphtheria-tetanus) Low or absent BTK protein or mRNA expression levels Detection of disease-causing mutations in the Btk gene", "contents": "X-Linked Agammaglobulinemia -- Evaluation. A\u00a0typical\u00a0diagnostic test sequence would evaluate serum levels of IgG, IgM, and IgA, the number of CD19-positive or CD20-positive B cells in circulation, humoral vaccine responses, BTK protein expression in peripheral monocytes, and Btk gene sequencing. Test results consistent with a diagnosis of XLA in a male patient with a history of recurrent bacterial infections would include finding: Serum levels of IgG, IgM, and IgA that are more than two standard deviations below age-matched controls Absence of mature B lymphocytes in the peripheral circulation (i.e., fewer than 1-2%) Little or no increase in antibody titers 3-4 weeks after\u00a0protein- or polysaccharide antigen vaccines\u00a0(e.g.,\u00a0immunizing against pneumococcal pneumonia or diphtheria-tetanus) Low or absent BTK protein or mRNA expression levels Detection of disease-causing mutations in the Btk gene"}
{"id": "article-31430_23", "title": "X-Linked Agammaglobulinemia -- Evaluation", "content": "Researchers have isolated several different mutations in the Btk gene. The finding of Btk gene mutations alone does not constitute a diagnosis. [10] [11] Findings which suggest a diagnosis of XLA in males whose B cell levels are below the 1 to 2% threshold\u00a0include all or most of the following: A\u00a0history of recurrent bacterial infections requiring one or more hospitalizations before the age of 5 years Poor humoral responses to vaccines No palpable tonsils or cervical lymph nodes Tests with abnormal results\u00a0should be\u00a0repeated\u00a0by independent testing\u00a0for confirmation\u00a0before beginning treatment or seeking referrals.", "contents": "X-Linked Agammaglobulinemia -- Evaluation. Researchers have isolated several different mutations in the Btk gene. The finding of Btk gene mutations alone does not constitute a diagnosis. [10] [11] Findings which suggest a diagnosis of XLA in males whose B cell levels are below the 1 to 2% threshold\u00a0include all or most of the following: A\u00a0history of recurrent bacterial infections requiring one or more hospitalizations before the age of 5 years Poor humoral responses to vaccines No palpable tonsils or cervical lymph nodes Tests with abnormal results\u00a0should be\u00a0repeated\u00a0by independent testing\u00a0for confirmation\u00a0before beginning treatment or seeking referrals."}
{"id": "article-31430_24", "title": "X-Linked Agammaglobulinemia -- Treatment / Management", "content": "There is no curative treatment for XLA. However, management\u00a0is by preventing, reducing,\u00a0and treating infections. [3] [1] The optimal\u00a0management of patients with XLA includes [21] [22] [23] [24] [23] [22] : Regular immunoglobulin replacement therapy, using intravenous or subcutaneous infusions Therapeutic and prophylactic use of antibiotics\u00a0to treat and prevent bacterial infections Careful monitoring to\u00a0manage reactions arising from immunoglobulin infusions, complications of infections, or the emergence of clinical disease (e.g., autoimmune, inflammatory, malignant) Support (nutritional, social, psychological, and educational) Counseling about the importance of\u00a0receiving all available immunizations except for those containing live bacteria or viruses, e.g., polio (OPV, oral polio vaccine), measles/mumps/rubella (MMR), chickenpox (Varivax), BCG, yellow fever, and\u00a0rotavirus (Rota-Teq)", "contents": "X-Linked Agammaglobulinemia -- Treatment / Management. There is no curative treatment for XLA. However, management\u00a0is by preventing, reducing,\u00a0and treating infections. [3] [1] The optimal\u00a0management of patients with XLA includes [21] [22] [23] [24] [23] [22] : Regular immunoglobulin replacement therapy, using intravenous or subcutaneous infusions Therapeutic and prophylactic use of antibiotics\u00a0to treat and prevent bacterial infections Careful monitoring to\u00a0manage reactions arising from immunoglobulin infusions, complications of infections, or the emergence of clinical disease (e.g., autoimmune, inflammatory, malignant) Support (nutritional, social, psychological, and educational) Counseling about the importance of\u00a0receiving all available immunizations except for those containing live bacteria or viruses, e.g., polio (OPV, oral polio vaccine), measles/mumps/rubella (MMR), chickenpox (Varivax), BCG, yellow fever, and\u00a0rotavirus (Rota-Teq)"}
{"id": "article-31430_25", "title": "X-Linked Agammaglobulinemia -- Treatment / Management", "content": "Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy requires several considerations:", "contents": "X-Linked Agammaglobulinemia -- Treatment / Management. Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy requires several considerations:"}
{"id": "article-31430_26", "title": "X-Linked Agammaglobulinemia -- Treatment / Management", "content": "A dose of 400 to 800 mg/kg every 3 to 4 weeks has been established to maintain an IgG trough greater than 5g/L. [25] Dose adjustments may be necessary for XLA patients with bronchiectasis and/or refractory infections such as meningoencephalitis. [17] [26]", "contents": "X-Linked Agammaglobulinemia -- Treatment / Management. A dose of 400 to 800 mg/kg every 3 to 4 weeks has been established to maintain an IgG trough greater than 5g/L. [25] Dose adjustments may be necessary for XLA patients with bronchiectasis and/or refractory infections such as meningoencephalitis. [17] [26]"}
{"id": "article-31430_27", "title": "X-Linked Agammaglobulinemia -- Treatment / Management", "content": "Both IVIG and SCIG are appropriate first-line therapies. IVIG may be preferred if a larger infusion volume due to a higher dose requirement is needed. SCIG has been reported to have a lower incidence of adverse reactions and allows for a more stable IgG trough following injection. [27]", "contents": "X-Linked Agammaglobulinemia -- Treatment / Management. Both IVIG and SCIG are appropriate first-line therapies. IVIG may be preferred if a larger infusion volume due to a higher dose requirement is needed. SCIG has been reported to have a lower incidence of adverse reactions and allows for a more stable IgG trough following injection. [27]"}
{"id": "article-31430_28", "title": "X-Linked Agammaglobulinemia -- Treatment / Management", "content": "Most adverse reactions are transient and pose no serious threat to the patient. These include immediate effects such as headache, fever, myalgia, hypo/hypertension, nausea, and chest pain. Reactions that resemble anaphylaxis are associated with higher transfusion rates\u00a0and occur during the infusion. Although IgA deficiency is associated with a risk of anaphylaxis during IVIG infusion, antibodies against IgA are unlikely in XLA patients due to agammaglobulinemia.\u00a0Reactions may temporarily require cessation of the infusion until\u00a0symptomatically managed with\u00a0agents such as NSAIDs (for flushing, pain, and headache), diphenhydramine (for pruritus, rashes, and flushing),\u00a0ondansetron (for nausea or vomiting) or muscle relaxants (for muscular spasm).", "contents": "X-Linked Agammaglobulinemia -- Treatment / Management. Most adverse reactions are transient and pose no serious threat to the patient. These include immediate effects such as headache, fever, myalgia, hypo/hypertension, nausea, and chest pain. Reactions that resemble anaphylaxis are associated with higher transfusion rates\u00a0and occur during the infusion. Although IgA deficiency is associated with a risk of anaphylaxis during IVIG infusion, antibodies against IgA are unlikely in XLA patients due to agammaglobulinemia.\u00a0Reactions may temporarily require cessation of the infusion until\u00a0symptomatically managed with\u00a0agents such as NSAIDs (for flushing, pain, and headache), diphenhydramine (for pruritus, rashes, and flushing),\u00a0ondansetron (for nausea or vomiting) or muscle relaxants (for muscular spasm)."}
{"id": "article-31430_29", "title": "X-Linked Agammaglobulinemia -- Treatment / Management", "content": "Delayed reactions are of greater concern, though less common, and include thromboembolism due to hyperviscosity, renal failure secondary to osmotic injury associated with sucrose-containing preparations, pseudohyponatremia, autoimmune hemolytic anemia, aseptic meningitis, and neutropenia. [28]", "contents": "X-Linked Agammaglobulinemia -- Treatment / Management. Delayed reactions are of greater concern, though less common, and include thromboembolism due to hyperviscosity, renal failure secondary to osmotic injury associated with sucrose-containing preparations, pseudohyponatremia, autoimmune hemolytic anemia, aseptic meningitis, and neutropenia. [28]"}
{"id": "article-31430_30", "title": "X-Linked Agammaglobulinemia -- Treatment / Management", "content": "To avoid adverse reactions, it is appropriate to adhere to a regimen with appropriate premedications and rate of infusion that has been previously well-tolerated by the patient.", "contents": "X-Linked Agammaglobulinemia -- Treatment / Management. To avoid adverse reactions, it is appropriate to adhere to a regimen with appropriate premedications and rate of infusion that has been previously well-tolerated by the patient."}
{"id": "article-31430_31", "title": "X-Linked Agammaglobulinemia -- Differential Diagnosis", "content": "The differential diagnosis for XLA is: Autosomal recessive agammaglobulinemia (ARA) Common variable immunodeficiency disease (CVID) Transient hypogammaglobulinemia of infancy (THI) X-linked hyper IgM syndrome (Hyper-IgM) X-linked lymphoproliferative disease (X-LPD) Severe combined immunodeficiency disease (SCID)", "contents": "X-Linked Agammaglobulinemia -- Differential Diagnosis. The differential diagnosis for XLA is: Autosomal recessive agammaglobulinemia (ARA) Common variable immunodeficiency disease (CVID) Transient hypogammaglobulinemia of infancy (THI) X-linked hyper IgM syndrome (Hyper-IgM) X-linked lymphoproliferative disease (X-LPD) Severe combined immunodeficiency disease (SCID)"}
{"id": "article-31430_32", "title": "X-Linked Agammaglobulinemia -- Pertinent Studies and Ongoing Trials", "content": "Immunoglobulin replacement therapy has been used for decades\u00a0and continues to be\u00a0the core treatment modality for patients with XLA. Although there are\u00a0isolated reports of successful\u00a0immune reconstitution using stem cell transplants from HLA-identical donors as well as attempts at gene replacement therapy, these approaches are not currently standard of care due to risks outweighing benefits. [3] [15] [16] [29]", "contents": "X-Linked Agammaglobulinemia -- Pertinent Studies and Ongoing Trials. Immunoglobulin replacement therapy has been used for decades\u00a0and continues to be\u00a0the core treatment modality for patients with XLA. Although there are\u00a0isolated reports of successful\u00a0immune reconstitution using stem cell transplants from HLA-identical donors as well as attempts at gene replacement therapy, these approaches are not currently standard of care due to risks outweighing benefits. [3] [15] [16] [29]"}
{"id": "article-31430_33", "title": "X-Linked Agammaglobulinemia -- Prognosis", "content": "Before regular immunoglobulin replacement therapy, most XLA died before the age of 10 from complications of lung disease, sepsis, or meningitis.\u00a0Although chronic lung disease persists as an important\u00a0factor in the\u00a0mortality in patients with XLA, life expectancy\u00a0extends into adulthood. [23] Affected individuals who get diagnosed early (i.e., before five years of age) receive regular immunoglobulin replacement therapy and are prescribed antibiotics treat or prevent infections can\u00a0be\u00a0expected to\u00a0have a\u00a0normal quality of life and live beyond the age of 40. [30]", "contents": "X-Linked Agammaglobulinemia -- Prognosis. Before regular immunoglobulin replacement therapy, most XLA died before the age of 10 from complications of lung disease, sepsis, or meningitis.\u00a0Although chronic lung disease persists as an important\u00a0factor in the\u00a0mortality in patients with XLA, life expectancy\u00a0extends into adulthood. [23] Affected individuals who get diagnosed early (i.e., before five years of age) receive regular immunoglobulin replacement therapy and are prescribed antibiotics treat or prevent infections can\u00a0be\u00a0expected to\u00a0have a\u00a0normal quality of life and live beyond the age of 40. [30]"}
{"id": "article-31430_34", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "XLA patients are at risk for complications\u00a0of the disease\u00a0itself as well as secondary to treatment.", "contents": "X-Linked Agammaglobulinemia -- Complications. XLA patients are at risk for complications\u00a0of the disease\u00a0itself as well as secondary to treatment."}
{"id": "article-31430_35", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "Complications associated with\u00a0XLA\u00a0usually arise from infections, especially\u00a0those that have become recurrent.\u00a0Susceptible individuals can become\u00a0chronically ill\u00a0and suffer\u00a0organ damage.\u00a0 For example, repeated episodes of acute pneumonia\u00a0may culminate in\u00a0chronic lung disease\u00a0and lead to bronchiectasis,\u00a0which has\u00a0the potential\u00a0to reduce\u00a0life expectancy. The likelihood\u00a0that chronic infections\u00a0will evolve into serious, life-threatening conditions increases with the length of delay in diagnosis. The later treatment begins, the more difficult it\u00a0is to eradicate the causative organisms\u00a0and prevent the systemic spread of infection to joints and vital organs. [7]", "contents": "X-Linked Agammaglobulinemia -- Complications. Complications associated with\u00a0XLA\u00a0usually arise from infections, especially\u00a0those that have become recurrent.\u00a0Susceptible individuals can become\u00a0chronically ill\u00a0and suffer\u00a0organ damage.\u00a0 For example, repeated episodes of acute pneumonia\u00a0may culminate in\u00a0chronic lung disease\u00a0and lead to bronchiectasis,\u00a0which has\u00a0the potential\u00a0to reduce\u00a0life expectancy. The likelihood\u00a0that chronic infections\u00a0will evolve into serious, life-threatening conditions increases with the length of delay in diagnosis. The later treatment begins, the more difficult it\u00a0is to eradicate the causative organisms\u00a0and prevent the systemic spread of infection to joints and vital organs. [7]"}
{"id": "article-31430_36", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "Complications associated with\u00a0chronic infections are, by far, the most common problem\u00a0confronted by patients with\u00a0XLA.\u00a0 Other, less common\u00a0complications include the increased\u00a0risk of developing\u00a0malignancy,\u00a0inflammatory conditions,\u00a0or\u00a0autoimmune disease.", "contents": "X-Linked Agammaglobulinemia -- Complications. Complications associated with\u00a0chronic infections are, by far, the most common problem\u00a0confronted by patients with\u00a0XLA.\u00a0 Other, less common\u00a0complications include the increased\u00a0risk of developing\u00a0malignancy,\u00a0inflammatory conditions,\u00a0or\u00a0autoimmune disease."}
{"id": "article-31430_37", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "Complications associated with\u00a0treatment are mainly those which arise from immunoglobulin replacement therapy. The replacement of immunoglobulin is a lifelong requirement for individuals with XLA.\u00a0\u00a0Indeed, regular immunoglobulin replacement therapy is known to increase life expectancy,\u00a0lower the\u00a0rate and severity of infections, decrease the number of hospitalizations,\u00a0and\u00a0reduce the need for antibiotics. Unfortunately, it also correlates with side effects\u00a0and must, therefore, have careful monitoring. Clinicians can overcome complications associated with immunoglobulin replacement therapy by changing (1) the time interval between immunoglobulin infusions,\u00a0(2) the route of administration, (3) the rate of administration, or (4) the product used for replacement. [31]", "contents": "X-Linked Agammaglobulinemia -- Complications. Complications associated with\u00a0treatment are mainly those which arise from immunoglobulin replacement therapy. The replacement of immunoglobulin is a lifelong requirement for individuals with XLA.\u00a0\u00a0Indeed, regular immunoglobulin replacement therapy is known to increase life expectancy,\u00a0lower the\u00a0rate and severity of infections, decrease the number of hospitalizations,\u00a0and\u00a0reduce the need for antibiotics. Unfortunately, it also correlates with side effects\u00a0and must, therefore, have careful monitoring. Clinicians can overcome complications associated with immunoglobulin replacement therapy by changing (1) the time interval between immunoglobulin infusions,\u00a0(2) the route of administration, (3) the rate of administration, or (4) the product used for replacement. [31]"}
{"id": "article-31430_38", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "Immunoglobulins used\u00a0in therapy derive from the pooled serum of thousands of healthy donors who have had screening for transmissible diseases. The donor serum is processed\u00a0to retain maximal amounts of\u00a0IgG\u00a0and only trace amounts of IgA and IgM, thus reducing\u00a0the likelihood of triggering anaphylactic reactions to IgA or\u00a0developing\u00a0kidney damage from complex formation induced by IgM.", "contents": "X-Linked Agammaglobulinemia -- Complications. Immunoglobulins used\u00a0in therapy derive from the pooled serum of thousands of healthy donors who have had screening for transmissible diseases. The donor serum is processed\u00a0to retain maximal amounts of\u00a0IgG\u00a0and only trace amounts of IgA and IgM, thus reducing\u00a0the likelihood of triggering anaphylactic reactions to IgA or\u00a0developing\u00a0kidney damage from complex formation induced by IgM."}
{"id": "article-31430_39", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "The length of\u00a0time between infusions\u00a0varies according to\u00a0the route of administration. The two most common routes of administering immunoglobulins are intravenous (IVIG)\u00a0and subcutaneous (SCIG).\u00a0 The interval between IVIG infusions can be as long as\u00a0a month, while the maximum interval between SCIG infusions\u00a0is usually no more than\u00a0a week. [32] [33]", "contents": "X-Linked Agammaglobulinemia -- Complications. The length of\u00a0time between infusions\u00a0varies according to\u00a0the route of administration. The two most common routes of administering immunoglobulins are intravenous (IVIG)\u00a0and subcutaneous (SCIG).\u00a0 The interval between IVIG infusions can be as long as\u00a0a month, while the maximum interval between SCIG infusions\u00a0is usually no more than\u00a0a week. [32] [33]"}
{"id": "article-31430_40", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "The rate of delivery and hence, the final immunoglobulin concentration obtained is another important factor. The\u00a0higher the rate of delivery, the greater the likelihood of complications. In situations where\u00a0higher immunoglobulin levels\u00a0are needed to combat a recalcitrant\u00a0infection, the clinician must balance the decision to increase the infusion rate against the side effect profile.", "contents": "X-Linked Agammaglobulinemia -- Complications. The rate of delivery and hence, the final immunoglobulin concentration obtained is another important factor. The\u00a0higher the rate of delivery, the greater the likelihood of complications. In situations where\u00a0higher immunoglobulin levels\u00a0are needed to combat a recalcitrant\u00a0infection, the clinician must balance the decision to increase the infusion rate against the side effect profile."}
{"id": "article-31430_41", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "Differences in the\u00a0exact composition of the product used for immunoglobulin\u00a0replacement also contributes to tolerability. The\u00a0purity and constituents (i.e., additives used to reduce the aggregate formation and enhance delivery) vary according to the manufacturer, and the reactions elicited vary in different individuals.", "contents": "X-Linked Agammaglobulinemia -- Complications. Differences in the\u00a0exact composition of the product used for immunoglobulin\u00a0replacement also contributes to tolerability. The\u00a0purity and constituents (i.e., additives used to reduce the aggregate formation and enhance delivery) vary according to the manufacturer, and the reactions elicited vary in different individuals."}
{"id": "article-31430_42", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "Reactions to immunoglobulin infusion therapy\u00a0can\u00a0be immediate or latent.\u00a0The most common immediate side effect is a headache. Headache occurs within minutes and is managed\u00a0using over-the-counter medications, although\u00a0it can often be avoided\u00a0altogether by simply\u00a0slowing the rate of infusion.", "contents": "X-Linked Agammaglobulinemia -- Complications. Reactions to immunoglobulin infusion therapy\u00a0can\u00a0be immediate or latent.\u00a0The most common immediate side effect is a headache. Headache occurs within minutes and is managed\u00a0using over-the-counter medications, although\u00a0it can often be avoided\u00a0altogether by simply\u00a0slowing the rate of infusion."}
{"id": "article-31430_43", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "Other common\u00a0infusion reactions include\u00a0nausea, malaise, fever/chills, chest tightness, and migraines. Infusion reactions can also categorize according to the system affected. Cardiovascular reactions include\u00a0tachycardia, palpitations, flushing, and\u00a0hypotension; neurologic reactions\u00a0include anxiety, nervousness, irritability, tremor, fainting and\u00a0seizures; respiratory system reactions include\u00a0cough, chest tightness, dyspnea, wheezing, and bronchospasm; dermatologic reactions include erythema, urticaria, and eczema; musculoskeletal reactions include low backache, arthralgia, and myalgia; and gastrointestinal reactions include\u00a0abdominal pain, distention, and liver dysfunction.", "contents": "X-Linked Agammaglobulinemia -- Complications. Other common\u00a0infusion reactions include\u00a0nausea, malaise, fever/chills, chest tightness, and migraines. Infusion reactions can also categorize according to the system affected. Cardiovascular reactions include\u00a0tachycardia, palpitations, flushing, and\u00a0hypotension; neurologic reactions\u00a0include anxiety, nervousness, irritability, tremor, fainting and\u00a0seizures; respiratory system reactions include\u00a0cough, chest tightness, dyspnea, wheezing, and bronchospasm; dermatologic reactions include erythema, urticaria, and eczema; musculoskeletal reactions include low backache, arthralgia, and myalgia; and gastrointestinal reactions include\u00a0abdominal pain, distention, and liver dysfunction."}
{"id": "article-31430_44", "title": "X-Linked Agammaglobulinemia -- Complications", "content": "More\u00a0serious complications can also\u00a0arise. These are much less common and occur\u00a0after a period of latency.\u00a0Examples include aseptic meningitis, anaphylactic reactions, Stevens-Johnson syndrome, erythema multiforme, acute renal failure, acute respiratory distress syndrome, transfusion-associated lung injury,\u00a0deep vein thrombosis, pulmonary edema, pulmonary embolism, cardiac arrest, shock, coma. [34]", "contents": "X-Linked Agammaglobulinemia -- Complications. More\u00a0serious complications can also\u00a0arise. These are much less common and occur\u00a0after a period of latency.\u00a0Examples include aseptic meningitis, anaphylactic reactions, Stevens-Johnson syndrome, erythema multiforme, acute renal failure, acute respiratory distress syndrome, transfusion-associated lung injury,\u00a0deep vein thrombosis, pulmonary edema, pulmonary embolism, cardiac arrest, shock, coma. [34]"}
{"id": "article-31430_45", "title": "X-Linked Agammaglobulinemia -- Deterrence and Patient Education", "content": "Patients and their families should\u00a0be provided\u00a0resources and educational materials informing them about vaccines, immunoglobulin replacement therapy, prophylactic and therapeutic use of antibiotics, routine and emergency medical care, the importance of keeping follow-up appointments,\u00a0healthcare team specialists,\u00a0preparation for\u00a0traveling, the importance of record-keeping, support, and\u00a0how to become a good\u00a0patient advocate. Reasons for avoiding\u00a0live virus vaccines,\u00a0such as oral polio, mumps, measles, rubella, rotavirus, yellow fever, chickenpox, should be explained\u00a0thoroughly. Patients and families should\u00a0be given the following advice when planning\u00a0a trip: Carry a portable water filtration system, prophylactic antibiotics, and other medications; Know the\u00a0vaccination requirements\u00a0for traveling to foreign countries; be prepared to comply or obtain formal exemptions; Carry an approved list of resources, including\u00a0the locations, contact information, hours of operation, for:", "contents": "X-Linked Agammaglobulinemia -- Deterrence and Patient Education. Patients and their families should\u00a0be provided\u00a0resources and educational materials informing them about vaccines, immunoglobulin replacement therapy, prophylactic and therapeutic use of antibiotics, routine and emergency medical care, the importance of keeping follow-up appointments,\u00a0healthcare team specialists,\u00a0preparation for\u00a0traveling, the importance of record-keeping, support, and\u00a0how to become a good\u00a0patient advocate. Reasons for avoiding\u00a0live virus vaccines,\u00a0such as oral polio, mumps, measles, rubella, rotavirus, yellow fever, chickenpox, should be explained\u00a0thoroughly. Patients and families should\u00a0be given the following advice when planning\u00a0a trip: Carry a portable water filtration system, prophylactic antibiotics, and other medications; Know the\u00a0vaccination requirements\u00a0for traveling to foreign countries; be prepared to comply or obtain formal exemptions; Carry an approved list of resources, including\u00a0the locations, contact information, hours of operation, for:"}
{"id": "article-31430_46", "title": "X-Linked Agammaglobulinemia -- Deterrence and Patient Education", "content": "infusion centers (to avoid interruption in the regular immunoglobulin replacement regimen) physicians and pharmacists (to obtain antibiotics needed to combat new infections) hospitals, medical specialists, emergency centers, therapists, and other support personnel Record keeping should be encouraged.\u00a0All aspects of patient care, management,\u00a0and follow-up should be included, as well as a list of contacts and resources that are\u00a0helpful to the patient.", "contents": "X-Linked Agammaglobulinemia -- Deterrence and Patient Education. infusion centers (to avoid interruption in the regular immunoglobulin replacement regimen) physicians and pharmacists (to obtain antibiotics needed to combat new infections) hospitals, medical specialists, emergency centers, therapists, and other support personnel Record keeping should be encouraged.\u00a0All aspects of patient care, management,\u00a0and follow-up should be included, as well as a list of contacts and resources that are\u00a0helpful to the patient."}
{"id": "article-31430_47", "title": "X-Linked Agammaglobulinemia -- Deterrence and Patient Education", "content": "Information regarding\u00a0the patient's\u00a0vaccination record, infection history, doctor/emergency department visits, hospitalizations, illnesses, days missed from school, therapist- and in-home care provider visits, lab test results, growth record, allergies, sensitivities, dietary preferences, medications, supplements; travel record, and social contacts and activities should be recorded.", "contents": "X-Linked Agammaglobulinemia -- Deterrence and Patient Education. Information regarding\u00a0the patient's\u00a0vaccination record, infection history, doctor/emergency department visits, hospitalizations, illnesses, days missed from school, therapist- and in-home care provider visits, lab test results, growth record, allergies, sensitivities, dietary preferences, medications, supplements; travel record, and social contacts and activities should be recorded."}
{"id": "article-31430_48", "title": "X-Linked Agammaglobulinemia -- Pearls and Other Issues", "content": "Early diagnosis is key in decreasing morbidity and mortality of patients with XLA Characterized by mutation of Btk, which prevents maturation of B-lymphocytes and subsequently the production of circulating immunoglobulin, resulting in severely impaired humoral immunity Look for a male infant or toddler (who no longer has protection from maternal IgG) with recurrent encapsulated organism infections requiring frequent hospitalizations and intravenous antibiotics Recurrent sinusitis, otitis, pneumonia, gastroenteritis Laboratory investigation reveals absent or very low levels of mature B-lymphocytes and circulating immunoglobulin The current mainstay of treatment is with\u00a0intravenous immunoglobulin Avoid live vaccines", "contents": "X-Linked Agammaglobulinemia -- Pearls and Other Issues. Early diagnosis is key in decreasing morbidity and mortality of patients with XLA Characterized by mutation of Btk, which prevents maturation of B-lymphocytes and subsequently the production of circulating immunoglobulin, resulting in severely impaired humoral immunity Look for a male infant or toddler (who no longer has protection from maternal IgG) with recurrent encapsulated organism infections requiring frequent hospitalizations and intravenous antibiotics Recurrent sinusitis, otitis, pneumonia, gastroenteritis Laboratory investigation reveals absent or very low levels of mature B-lymphocytes and circulating immunoglobulin The current mainstay of treatment is with\u00a0intravenous immunoglobulin Avoid live vaccines"}
{"id": "article-31430_49", "title": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes", "content": "XLA is one of the most common primary immunodeficiencies occurring in the pediatric population. Males over the age of 6 months present with recurrent infections due to encapsulated organisms because they lack the ability to produce mature B-lymphocytes and subsequently circulating immunoglobulin.\u00a0 This disease does not present at birth because maternal IgG provides immune defense during the earliest months of life. The initial presentations of XLA occur most commonly in the pediatric primary care and inpatient hospitalist settings. The involvement of multiple disciplines is vital to improving the outcomes of patients with XLA so that diagnosis can take place as early as possible, with streamlined treatment.", "contents": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes. XLA is one of the most common primary immunodeficiencies occurring in the pediatric population. Males over the age of 6 months present with recurrent infections due to encapsulated organisms because they lack the ability to produce mature B-lymphocytes and subsequently circulating immunoglobulin.\u00a0 This disease does not present at birth because maternal IgG provides immune defense during the earliest months of life. The initial presentations of XLA occur most commonly in the pediatric primary care and inpatient hospitalist settings. The involvement of multiple disciplines is vital to improving the outcomes of patients with XLA so that diagnosis can take place as early as possible, with streamlined treatment."}
{"id": "article-31430_50", "title": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes", "content": "Appropriate care team members for a patient with XLA would most likely include a pediatrician,\u00a0immunologist, and pulmonologist, as well as other specialists who can contribute to the care of complications and comorbidities associated with XLA. Pathologists and radiologists can aid in the early diagnosis of XLA, while pharmacists can help clinicians select appropriate treatment regimens and perform medication reconciliation. Nursing should be able to counsel the family, answer questions, and assess the progress of treatment. This interprofessional team approach will lead to better outcomes, and give the family/patient more resources form which to access care and information about XLA. [Level V] Family members or caretakers should be encouraged to take part in the patient\u2019s care and learn how to become effective patient advocates, with the goal of transferring advocacy skills to the patient.", "contents": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes. Appropriate care team members for a patient with XLA would most likely include a pediatrician,\u00a0immunologist, and pulmonologist, as well as other specialists who can contribute to the care of complications and comorbidities associated with XLA. Pathologists and radiologists can aid in the early diagnosis of XLA, while pharmacists can help clinicians select appropriate treatment regimens and perform medication reconciliation. Nursing should be able to counsel the family, answer questions, and assess the progress of treatment. This interprofessional team approach will lead to better outcomes, and give the family/patient more resources form which to access care and information about XLA. [Level V] Family members or caretakers should be encouraged to take part in the patient\u2019s care and learn how to become effective patient advocates, with the goal of transferring advocacy skills to the patient."}
{"id": "article-31430_51", "title": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes", "content": "Records should also include a useful contact\u00a0list regarding\u00a0healthcare team members, for physicians, staff, physician assistants,\u00a0therapists, nurses, specialists, specialty centers (e.g., for immunoglobulin replacement therapy), hospitals, pharmacies, support groups, and insurance providers.", "contents": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes. Records should also include a useful contact\u00a0list regarding\u00a0healthcare team members, for physicians, staff, physician assistants,\u00a0therapists, nurses, specialists, specialty centers (e.g., for immunoglobulin replacement therapy), hospitals, pharmacies, support groups, and insurance providers."}
{"id": "article-31430_52", "title": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes", "content": "The patient needs to understand the necessity for regular follow-up visits. Patients should receive advance information regarding the specialists that they need to see, the tests that are necessary (e.g. routine blood tests, determination of lymphocyte subsets and immunoglobulin levels; liver function tests; hepatitis screening; pulmonary function tests; CT scans) and the\u00a0role that the resulting information will\u00a0play in monitoring treatment responses and stemming disease progression.", "contents": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes. The patient needs to understand the necessity for regular follow-up visits. Patients should receive advance information regarding the specialists that they need to see, the tests that are necessary (e.g. routine blood tests, determination of lymphocyte subsets and immunoglobulin levels; liver function tests; hepatitis screening; pulmonary function tests; CT scans) and the\u00a0role that the resulting information will\u00a0play in monitoring treatment responses and stemming disease progression."}
{"id": "article-31430_53", "title": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes", "content": "Randomized-controlled trials (RCTs) supporting the best treatment methods are very limited due to the rare nature of XLA.\u00a0 Additionally,\u00a0the poor prognosis associated with a lack of treatment\u00a0ethically prevents\u00a0such studies. Current recommendations are made based on an exhaustive review of current\u00a0case reports and case series of XLA cases from peer-reviewed journals, as well as small RCTs regarding the treatment of primary immunodeficiencies in general.\u00a0 Expert opinion from an interprofessional team may be necessary when current evidence fails to provide a definitive recommendation for treatment modalities. Overall, an interprofessional team approach to the treatment of patients with XLA is the proper management methodology.", "contents": "X-Linked Agammaglobulinemia -- Enhancing Healthcare Team Outcomes. Randomized-controlled trials (RCTs) supporting the best treatment methods are very limited due to the rare nature of XLA.\u00a0 Additionally,\u00a0the poor prognosis associated with a lack of treatment\u00a0ethically prevents\u00a0such studies. Current recommendations are made based on an exhaustive review of current\u00a0case reports and case series of XLA cases from peer-reviewed journals, as well as small RCTs regarding the treatment of primary immunodeficiencies in general.\u00a0 Expert opinion from an interprofessional team may be necessary when current evidence fails to provide a definitive recommendation for treatment modalities. Overall, an interprofessional team approach to the treatment of patients with XLA is the proper management methodology."}
{"id": "article-31430_54", "title": "X-Linked Agammaglobulinemia -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "X-Linked Agammaglobulinemia -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}